达尔西利在乳腺癌治疗中的研究进展
Progression of Dalpiciclib in the treatment of breast cancer
秦莉莉 1张少华 1宋华 1董晓培 1李凡1
作者信息
- 1. 100071 北京 解放军总医院第五医学中心肿瘤内科
- 折叠
摘要
乳腺癌是目前世界上发病率最高的恶性肿瘤.美国国家癌症研究所监测、流行病学和最终结果数据库(SEER)显示,激素受体阳性(HR+)乳腺癌占比超过 70%,而内分泌治疗是HR+晚期乳腺癌的主要治疗手段之一.多项研究证实,在内分泌治疗的基础上联合 CDK4/6 抑制剂可以显著改善HR+晚期乳腺癌患者的预后.目前临床应用的CDK4/6 抑制剂主要有哌柏西利、阿贝西利和瑞博西利.达尔西利是中国自主研发的第 1 款CDK4/6 抑制剂,为 1.1 类创新药,是全球第 4种CDK4/6 抑制剂,在不同分期乳腺癌中均显示出一定疗效.现就达尔西利在不同类型乳腺癌中的相关研究作一综述,以期为达尔西利在未来乳腺癌治疗中的应用提供参考.
Abstract
Currently,breast cancer prevails as the most common malignancy throughout the world.According to Surveillance,Epidemiology,and End Results(SEER)database,hormone receptor-positive(HR+)breast cancer accounts for more than 70%of all breast cancer patients.As well,endocrine therapy is one of the main modalities for the treatment of HR+ advanced breast cancer.Several studies have confirmed that endocrine therapy combined with CDK4/6 inhibitors can significantly improve the prognosis of HR+ advanced breast cancer.Currently CDK4/6 inhibitors including Palbociclib,Abemaciclib,and Ribociclib are applied in clinic.Dalpiciclib is the first CDK4/6 inhibitor independently developed by China,which is a class 1.1 innovative drug.In this article,we review relevant studies of Dalpiciclib in breast cancer,and provide references for Dalpiciclib in the future treatment of breast cancer.
关键词
乳腺癌/达尔西利/CDK4/6抑制剂/疗效Key words
Breast cancer/Dalpiciclib/Cyclin dependent kinase 4/6(CDK4/6)inhibitors/Curative effect引用本文复制引用
基金项目
北京医学奖励基金会项目(YXJL-2020-0941-0751)
出版年
2024
NETL
NSTL
万方数据